Inclusion Criteria:  -  Inclusion Criteria for subjects with impaired kidney function:  Sign the informed consent before the trial, and fully understand the content, process, and possible adverse reactions of the trial; Male or female subjects aged 18 to 70 (including 18 and 70); Body mass index (BMI) ranges from 18 kg/m2 to 28 kg/m2 (including 18 and 28); The glomerular filtration rate should meet the following criteria (GFR, mL/min):Subjects with mild renal impairment (CKD2): 60-89 mL/min (including 60-89);Subjects with moderate renal impairment (CKD3): 30-59 mL/min (including 30-59 ends); Renal function should be stable, and the GFR results should be tested twice before administration (at least 3 days apart) within the same CKD stage.  Inclusion Criteria for subjects with normal kidney function:  Sign the informed consent before the trial and fully understand the content, process, and possible adverse reactions of the trial; Male or female subjects aged 18 to 70 (including 18 and 70); Body mass index (BMI) ranges from 18 kg/m2 to 28 kg/m2 (including 18 and 28); Glomerular filtration rate (GFR) ≥90 mL/min.  Exclusion Criteria:  -  Exclusion Criteria for subjects with impaired kidney function:  History of kidney transplant; Need Renal dialysis during the study; Urinary incontinence or anuria; Clinically significant heart disease, including but not limited to: congestive heart failure, symptomatic coronary artery disease, myocardial infarction, QTcF≥470 ms (female) or QTcF≥450 ms (male) within 12 months before the start of treatment; Received any investigational drug within 3 months before the study started; Taking any drugs which can affect the metabolic enzyme CYP3A within 14 days before the study started; Smokers and alcoholics, or those screened positive for alcohol; History of drug use, or drug abuse screening positive.  Exclusion Criteria for subjects with normal kidney function:  History of kidney transplant; Clinically significant heart disease, including but not limited to: congestive heart failure, symptomatic coronary artery disease, myocardial infarction, QTcF≥470 ms (female) or QTcF≥450 ms (male) within 12 months before the start of treatment; Received any investigational drug within 3 months before the study started; Taking any drugs which can affect the metabolic enzyme CYP3A within 14 days before the study started; Smokers and alcoholics, or those screened positive for alcohol; History of drug use, or drug abuse screening positive.